Compounds > 3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic acid
Page last updated: 2024-10-21

3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic acid and Intracranial Hypertension

3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic acid has been researched along with Intracranial Hypertension in 1 studies

3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic acid: structure given in first source; NMDA receptor antagonist

Intracranial Hypertension: Increased pressure within the cranial vault. This may result from several conditions, including HYDROCEPHALUS; BRAIN EDEMA; intracranial masses; severe systemic HYPERTENSION; PSEUDOTUMOR CEREBRI; and other disorders.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Oertel, M1
Kelly, DF1
Lee, JH1
Glenn, TC1
Vespa, PM1
Martin, NA1

Other Studies

1 other study available for 3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic acid and Intracranial Hypertension

ArticleYear
Is CPP therapy beneficial for all patients with high ICP?
    Acta neurochirurgica. Supplement, 2002, Volume: 81

    Topics: Anticonvulsants; Blood Pressure; Brain Injuries; Humans; Intracranial Hypertension; Intracranial Pre

2002